Clinical trial
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
NCT00437294 · Eli Lilly and Company, Industry · Terminated
Key facts
| NCT number | NCT00437294 |
|---|---|
| Title | Enzastaurin in Combination of Capecitabine to Treat Breast Cancer |
| Official title | A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin, placebo, capecitabine |
| Enrollment | 86 |
| Start date | Mar 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Feb 19, 2007 |
| Last update posted | Aug 10, 2020 |
| Countries | Argentina, Australia, France, Mexico, South Africa |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: